Autoimmune diseases and myelodysplastic syndromes

Komrokji, Rami; Kulasekararaj, Austin; Ali, Najla H Al; Kordasti, Shahram; Bart-Smith, Emily; Craig, Benjamin M.; Padron, Eric; Zhang, Ling; Lancet, Jeffrey E.; Pinilla‐Ibarz, Javier; List, Alan F.; Mufti, Ghulam J.; Epling-Burnette, Pearlie K.

doi:10.1002/ajh.24333

Cited by 121 publications

(104 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6] Similarly, in a large MDS study (n ¼ 1408), 391 patients (28%) were found to have AID, with HT (44%) being most common, followed by ITP (12%) and RA (10%). [7] In this study, AID were associated with a protective effect, with affected patients having a better OS and leukemia-free survival. [7] The role of the ''inflammasome'' in MDS/CMML is extensively being explored.…”

mentioning

confidence: 59%

“…[7] In this study, AID were associated with a protective effect, with affected patients having a better OS and leukemia-free survival. [7] The role of the ''inflammasome'' in MDS/CMML is extensively being explored. The inflammasome is an intracellular protein complex consisting of NRLP3 (nucleotide-binding domain and leucine rich repeat containing family), apoptosis-associated speck protein with a caspase activation and recruitment domain (ASC), and caspase-1.…”

mentioning

confidence: 59%

“…[1,3] Similar to MDS and MPN, CMML is also closely associated with inflammation and autoimmune diseases (AID). [6,7] Affected patients tend to have a pro-inflammatory state with cytokine mediated symptoms (fevers, chills night sweats, and fatigue), capillary leak and inflammatory organ involvement (acute lung injury, vasculitis, arthritis, and Sweets syndrome). AID such as Hashimoto's thyroiditis (HT) and idiopathic thrombocytopenic purpura (ITP) are relatively frequent.…”

mentioning

confidence: 99%

“…AID such as Hashimoto's thyroiditis (HT) and idiopathic thrombocytopenic purpura (ITP) are relatively frequent. [7] In this issue of the journal, Elbaek et al carry out a case-control study, evaluating chronic inflammatory and AID in 112 patients with CMML and 231 unmatched controls with chronic lymphocytic leukemia (CLL). [8] They observe that 16.1% of CMML subjects and 6.5% of CLL controls presented with a history of chronic inflammatory or AID and that this finding was associated with an increased risk of developing CMML [adjusted OR 3.24, 95% CI 1.5-7.0].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Chronic myelomonocytic leukemia: molecularly contaminated, but not defined

Patnaik

Tefferi

2016

Leukemia & Lymphoma

View full text Add to dashboard Cite

mentioning

confidence: 59%

mentioning

confidence: 59%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Chronic myelomonocytic leukemia: molecularly contaminated, but not defined

Patnaik

Tefferi

2016

Leukemia & Lymphoma

View full text Add to dashboard Cite

“…Die Inzidenz von autoimmun-entzündlichen Manifestationen (AIM) bei MDS wird in Studien mit 10-20 % angegeben [6]. Umgekehrt findet sich therapieunabhän-gig eine erhöhte Inzidenz von MDS/AML im Kontext primärer Autoimmunerkrankungen [7,8]. Unter den AIM bei MDS dominieren vaskulitische Syndrome, insbesondere in kutaner Manifestation [9].…”

Section: Mds-assoziierte Autoimmunphänomeneunclassified

Myelodysplastisches Syndrom, akute Leukämie und Stammzelltransplantation

et al. 2017

View full text Add to dashboard Cite

Diagnosis and Treatment of Myelodysplastic Syndromes

Sekeres

Taylor

2022

JAMA

View full text Add to dashboard Cite

he myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are a group of cancers characterized by failure of bone marrow stem cells to mature into normal-functioning blood cells. MDS are characterized by reduced numbers of peripheral blood cells, an increased risk of acute myeloid leukemia transformation, and reduced survival, with a 5-year survival rate of approximately 37%. 1,2 The yearly incidence of MDS is approximately 4 per 100 000 people. 3 MDS are more common in men (with yearly incidence rates of approxi-mately 5.4 per 100 000 vs 2.9 per 100 000 for women) and are more common among people who are White compared with people who are Asian/Pacific Islander (4.0 per 100 000), Black (2.7 per 100 000), or Hispanic (2.9 per 100 000), and among people who are older. 3 The median age of diagnosis is approximately 70 years, and the yearly incidence rate increases to 25 per 100 000 in people aged 65 years and older. 3 Older age is associated with clonal hematopoiesis of indeterminate potential, which is considered a precursor to MDS. 4 Additional risk factors IMPORTANCE Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow dysplasia along with anemia, neutropenia, or thrombocytopenia. MDS are associated with an increased risk of acute myeloid leukemia (AML). The yearly incidence of MDS is approximately 4 per 100 000 people in the United States and is higher among patients with advanced age.OBSERVATIONS MDS are characterized by reduced numbers of peripheral blood cells, an increased risk of acute myeloid leukemia transformation, and reduced survival. The median age at diagnosis is approximately 70 years, and the yearly incidence rate increases to 25 per 100 000 in people aged 65 years and older. Risk factors associated with MDS include older age and prior exposures to toxins such as chemotherapy or radiation therapy. MDS are more common in men compared with women (with yearly incidence rates of approximately 5.4 vs 2.9 per 100 000). MDS typically has an insidious presentation, consisting of signs and symptoms associated with anemia, thrombocytopenia, and neutropenia. MDS can be categorized into subtypes that are associated with lower or higher risk for acute myeloid leukemia transformation and that help with therapy selection. Patients with lower-risk MDS have a median survival of approximately 3 to 10 years, whereas patients with higher-risk disease have a median survival of less than 3 years. Therapy for lower-risk MDS is selected based on whether the primary clinical characteristic is anemia, thrombocytopenia, or neutropenia. Management focuses on treating symptoms and reducing the number of required transfusions in patients with low-risk disease. For patients with lower-risk MDS, erythropoiesis stimulating agents, such as recombinant humanized erythropoietin or the longer-acting erythropoietin, darbepoetin alfa, can improve anemia in 15% to 40% of patients for a median of 8 to 23 months. For th...

show abstract

Autoimmune diseases and myelodysplastic syndromes

Cited by 121 publications

References 17 publications

Chronic myelomonocytic leukemia: molecularly contaminated, but not defined

Chronic myelomonocytic leukemia: molecularly contaminated, but not defined

Myelodysplastisches Syndrom, akute Leukämie und Stammzelltransplantation

Diagnosis and Treatment of Myelodysplastic Syndromes

Contact Info

Product

Resources

About